No abstract

No abstract

Mental disorders are severe, disabling conditions with unknown etiology and are commonly misdiagnosed when clinical symptomology criteria are solely used. Our previous work indicated that combination of serum levels of multiple proteins in tissue plasminogen activator (tPA)-brain-derived neurotrophic factor (BDNF) pathway improved accuracy of diagnosis of major depressive disorder (MDD). Here, we measured serum levels of tPA, plasminogen activator inhibitor-1 (PAI-1), BDNF, precursor-BDNF (proBDNF), tropomyosin-related kinase B (TrkB) and neurotrophin receptor p75 (p75NTR) in patients with paranoid schizophrenia (SZ, n = 34), MDD (n = 30), bipolar mania (BM, n = 30), bipolar depression (BD, n = 22), panic disorder (PD, n = 30), and healthy controls (HCs, n = 30) by Enzyme-linked immunosorbent assay kits. We used receiver operating characteristic (ROC) curve to analyze diagnostic potential of these proteins. We found, compared with HCs, that serum tPA and proBDNF were lower in SZ, BM and BD; TrkB was lower in SZ and BD; and p75NTR was declined in SZ and BM. ROC analysis showed that combined serum level of tPA, PAI-1, BDNF, proBDNF, TrkB and p75NTR was better than any single protein in accuracy of diagnosis and differentiation, suggesting that the combination of multiple serum proteins levels in tPA-BDNF pathway may have a potential for a diagnostic panel in mental disorders.

Aims This systematic review and meta‐analysis aimed to evaluate the effects of cognitive‐behavioural therapy in patients with inflammatory bowel diseases. Methods Cochrane Library, Web of Science, Pubmed, EMBASE, and CINAHL were searched up to June 2017, as well as grey literature and databases hand searches. Quality assessment, heterogeneity, sensitivity analysis, and publication bias were performed. Stata12.0 software was used for pooled estimates. Results Seven eligible reports were included in the final analysis. Inflammatory Bowel Disease Questionnaire score was higher in the cognitive‐behavioural therapy group than in the control group at the final follow‐up in inflammatory bowel disease patients (P = 0.008). There was no statistically significant difference in the Crohn's Disease Activity Index (P = 0.751), Simple Clinical Colitis Activity Index score (P = 0.747), State Anxiety score (P = 0.988), Trait Anxiety score (P = 0.681), and Perceived Stress Questionnaire score (P = 0.936) at the final point of follow‐up. A funnel plot showed no publication bias (P = 0.98). Conclusion Cognitive‐behavioural therapy appeared to support higher quality of life in inflammatory bowel disease patients compared with a control group at the final follow‐up point but had no effect on disease activity, anxiety, or perceived stress in patients with inflammatory bowel disease. Cognitive‐behavioural therapy can be an acceptable adjunctive therapy for inflammatory bowel disease patients, but the effect of cognitive‐behavioural therapy is limited.